Advantage of combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenografts

Radiation Research

Volumn 168, Issue 1, 2007, Pages 65-71

  Papadopoulou, Maria V ^a,d   Bloomer, William D ^a   Taylor, Alice P ^b   Hernandez, Marisol ^b   Blumenthal, Rosalyn D ^b   Hollingshead, Melinda G ^c  

^a Evanston Northwestern Healthcare ^*  (United States)

^b GARDEN STATE CANCER CENTER   (United States)

^c DTP   (United States)

^d EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIN; DNA; NLCQ 1; NSC 709257; PIMONIDAZOLE; UNCLASSIFIED DRUG; 4 (3 (2 NITRO 1 IMIDAZOLYL) PROPYLAMINO) 7 CHLOROQUINOLINE HYDROCHLORIDE; 4-(3-(2-NITRO-1-IMIDAZOLYL)-PROPYLAMINO)-7-CHLOROQUINOLINE HYDROCHLORIDE; IMIDAZOLE DERIVATIVE; QUINOLINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER STAGING; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; HEAD AND NECK SURGERY; HEAD AND NECK TUMOR; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; IRRADIATION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE; RADIOTHERAPY; REST; TUMOR VOLUME; WEIGHT; XENOGRAFT; ANIMAL; DIET THERAPY; DRUG SCREENING; PATHOLOGY; RADIATION RESPONSE; TUMOR CELL LINE;

MUS MUSCULUS;

ANIMALS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; QUINOLINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34548585717     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR0539.1     Document Type: Article

References (34)

1. J. M. Brown, Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies. Mol. Med. Today 6, 157-162 (2000).
2. A. L. Harris, Hypoxia - a key regulatory factor in tumor growth. Nat. Rev. Cancer 2, 3338-3347 (2002).
3. D. M. Brizel, G. S. Sibley, L. R. Prosnitz, R. L. Scher and M. W. Dewhirst, Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 38, 285-289 (1997).
4. D. M. Brizel, R. K. Dodge, R. W. Clough and M. W. Dewhirst, Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother. Oncol. 53, 113-117 (1999).
5. I. J. Stratford and P. Workman, Bioreductive drugs into the next millennium. Anticancer Drug Design 13, 519-528 (1998).
6. W. Dobrowsky, J. Naude, E. Dobrowsky, W. Millesi, R. Pavelka, M. Grasl, W. Kohler, M. Kautzky and M. Reichel, Mitomycin c (MMC) and unconventional fractionation (V-CHART) in advance head and neck cancer. Acta Oncol. 34, 268-272 (1995).
7. B. G. Haffty, Y. H. Son, R. Papac, C. T. Sasaki, J. B. Weissberg, D. Fischer, S. Rockwell, A. C. Sartorelli and J. J. Fischer, Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: Results of the Yale mitomycin randomized trials. J. Clin. Oncol. 15, 268-276 (1997).
8. D-J. Lee, A. Trotti, S. Spencer, R. Rostock, C. Fisher, R. von Roemeling, E. Harvey and E. Groves, Concurrent tirapazamine arid radiotherapy for advanced head and neck carcinomas: A phase II study. Int. J. Radiat. Oncol. Biol. Phys. 42, 811-815 (1998).
9. J. Treat, E. Johnson, C. Langer, C. Belani, B. Haynes, R. Greenberg, R. Rodriquez, P. Drobins, W. Miller and J. Viallet, Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: A phase II study. J. Clin. Oncol. 16, 3524-3527 (1998).
10. J. von Pawel, R. von Roemeling, U. Gatzemeier, M. Boyer, L. O. Elisson, P. Clark, D. Talbot, A. Rey, T. W. Butler and J. Treat, Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. J. Clin. Oncol. 18, 1351-1359 (2000).
11. V. M. Aquino, S. D. Weitman, N. J. Winick, S. Blaney, W. L. Furman, J. L. Kepner, P. Bonate, M. Krailo, W. Qu and M. Bernstein, Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: A pediatric oncology group study. J. Clin. Oncol. 22, 1413-1419 (2004).
12. M. V. Papadopoulou, M. Ji, M. K. Rao and W. D. Bloomer, 4-[3-(2-Nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin. Oncol. Res. 12, 185-192 (2000).
13. M. V. Papadopoulou and W. D. Bloomer, NLCQ-1 (NSC 709257): Exploiting hypoxia with a weak DNA-intercalating bioreductive drug. Clin. Cancer Res. 9, 5714-5720 (2003).
14. M. V. Papadopoulou and W. D. Bloomer, Exploiting hypoxia in solid tumors with DNA-targeted bioreductive drugs. Drugs of the Future 29, 807-819 (2004).
15. J. M. Reid, D. P. Squillace and M. M. Ames, Single dose pharmacokinetics of the DNA-binding bioreductive agent NLCQ-1 (NSC 709257) in CD2F1 mice. Cancer Chem. Pharmacol. 51, 483-487 (2003).
16. M. V. Papadopoulou, W. D. Bloomer and M. G. Hollingshead, NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts. Anticancer Res. 25, 1865-1870 (2005).
17. J. Plowman, D. J. Dykes, M. Hollingshead, L. Simpson-Herren and M. C. Alley, Human tumor xenograft models in NCI drug development. In Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval (B. Teicher, Ed.), pp. 101-125. Humana Press, Totowa, NJ, 1997.
18. A. P. Taylor, L. Osorio, R. Craig, J. A. Raleigh, Z. Ying, D. M. Goldenberg and R. D. Blumenthal, Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy. Clin. Cancer Res. 8, 1213-1222 (2002).
19. H-A. Lehr, C. M. van der Loos, P. Teeling and A. M. Gown, Complete chromogen separation and analysis in double immunohistochemical stains using Photoshop-based image analysis. J. Histochem. Cytochem. 47, 119-125 (1999).
20. D. J. Dykes, B. J. Abbott, J. G. Mayo, S. D. Harrison, W. R. Laster, L. Simpson-Herren and D. P. Griswold, Development of human tumor xenograft models for in vivo evaluation of new antitumor drugs. Contrib. Oncol. 42, 1-22 (1992).
21. W. Van den Bogaert, E. van der Schueren, J. C. Horiot, M. De Vilhena, S. Schraub, V. Svoboda, G. Arcangeli, M. de Pauw and M. Van Glabbeke, The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects. Radiother. Oncol. 35, 91-99 (1995).
22. D. J. Lee, D. Cosmatos, V. A. Marcial, K. K. Fu, M. Rotman, J. S. Cooper, H. G. Ortiz, J. J. Beitler, R. A. Abrams and W. J. Curran, Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 32, 567-576 (1995).
23. F. Eschwege, H. Sancho-Garnier, D. Chassagne, D. Brisgand, M. Guerra, E. P. Malaise, P. Bey, L. Busutti, L. Cionini and C. Hill, Results of a European randomized trial of Etanidazole combined with radiotherapy in head and neck carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 39, 275-281 (1997).
24. J. Overgaard, Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol. Res. 6, 509-518 (1994).
25. C. P. Cottrill, K. Bishop, M. I. Walton and J. M. Henk, Pilot study of nimorazole as a hypoxic-cell sensitizer with the "chart" regimen in head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 42, 807-810 (1998).
26. J. Overgaard, H. S. Hansen, M. Overgaard, L. Bastholt, A. Berthelsen, L. Specht, B. Lindelov and K. Jorgensen, A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish head and neck cancer study (DAHANCA) Protocol 5-85. Radiother. Oncol. 46, 135-146 (1998).
27. W. Dobrowsky, J. Naude, J. Widder, E. Dobrowsky, W. Millesi, R. Pavelka, C. Grasl and M. Reichel, Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 42, 803-806 (1998).
28. V. Budach, M. Stuschke, W. Budach, M. Baumann, D. Geismar, G. Grabenbauer, I. Lammert, K. Jahnke, G. Stueben and K. D. Wernecke, Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J. Clin. Oncol. 23, 1125-1135 (2005).
29. D. Rischin, L. Peters, R. Fisher, A. Macann, J. Denham, M. Poulsen, M. Jackson, L. Kenny, M. Penniment and B. McClure, Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized Phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J. Clin. Oncol. 23, 79-87 (2005).
30. K. L. Bennewith, J. A. Raleigh and R. E. Durand, Orally administered pimonidazole to label hypoxic tumors cells. Cancer Res. 62, 6827-6830 (2002).
31. M. V. Papadopoulou, M. Ji, M. K. Rao and W. D. Bloomer, 4-[3-(2-Nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1). A novel bioreductive agent as radiosensitizer in vitro and in vivo. Comparison with tirapazamine. Oncol. Res. 12, 325-333 (2000).
32. J. M. Brown and A. J. Giaccia, Tumor hypoxia: The picture has changed in the 1990s. Int. J. Radiat. Biol. 65, 95-102 (1994).
33. R. D. Blumenthal, A. Taylor, L. Osorio, R. Ochakovskaya, J. Raleigh, M. Papadopoulou, W. D. Bloomer and D. M. Goldenberg, Optimizing the use of combined radio-immunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia. Int. J. Cancer 94, 564-571 (2001).
34. M. V. Papadopoulou, M. Ji, M. K. Rao and W. D. Bloomer, Reductive activation of the nitroimidazole-based hypoxia-selective cytotoxin NLCQ-1 (NSC 709257). Oncol. Res. 14, 21-29 (2003).